New hope for chronic coughers: experimental drug enters final testing phase

NCT ID NCT07650084

Recruiting now Symptom relief Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called BLU-5937 in adults who have had a stubborn cough for at least a year that hasn't improved with other treatments. About 75 people in China will receive either the drug or a placebo for 24 weeks to see if it reduces coughing and is safe. The goal is to find a new option for people whose chronic cough severely affects their daily life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Chronic Cough Cough

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

REFRACTORY CHRONIC COUGH

Contacts and locations

Locations

GSK Investigational Site
RECRUITING

Leshan, Sichuan, 614003, China
GSK Investigational Site
RECRUITING

Beijing, 100730, China
GSK Investigational Site
RECRUITING

Changsha, 410008, China
GSK Investigational Site
RECRUITING

Chengdu, 610021, China
GSK Investigational Site
RECRUITING

Chengdu, 610041, China
GSK Investigational Site
RECRUITING

Chongqing, 408099, China
GSK Investigational Site
RECRUITING

Dongguan, 523326, China
GSK Investigational Site
RECRUITING

Ganzhou, 341000, China
GSK Investigational Site
RECRUITING

Guangzhou, 510000, China
GSK Investigational Site
RECRUITING

Guangzhou, 510260, China
GSK Investigational Site
RECRUITING

Guilin, 541002, China
GSK Investigational Site
RECRUITING

Hangzhou, 310003, China
GSK Investigational Site
RECRUITING

Hefei, 230001, China
GSK Investigational Site
RECRUITING

Hefei, 230022, China
GSK Investigational Site
RECRUITING

Hohhot, 010017, China
GSK Investigational Site
RECRUITING

Huizhou, 516000, China
GSK Investigational Site
RECRUITING

Huizhou, 516001, China
GSK Investigational Site
RECRUITING

Jiangsu, 221004, China
GSK Investigational Site
RECRUITING

Jinan, 250021, China
GSK Investigational Site
RECRUITING

Kunming, 650032, China
GSK Investigational Site
RECRUITING

Liuzhou, China
GSK Investigational Site
RECRUITING

Meizhou, 514700, China
GSK Investigational Site
RECRUITING

Nanchang, 330038, China
GSK Investigational Site
RECRUITING

Pingxiang, 337055, China
GSK Investigational Site
RECRUITING

Shanghai, 200032, China
GSK Investigational Site
RECRUITING

Shanghai, 200065, China
GSK Investigational Site
RECRUITING

Shanghai, 200080, China
GSK Investigational Site
RECRUITING

Shenyang, 110004, China
GSK Investigational Site
RECRUITING

Shenzhen, 518053, China
GSK Investigational Site
RECRUITING

Taizhou, 317000, China
GSK Investigational Site
RECRUITING

Ürümqi, 830001, China
GSK Investigational Site
RECRUITING

Weifang, China
GSK Investigational Site
RECRUITING

Wuxi, 214023, China
GSK Investigational Site
RECRUITING

Xiamen, 361004, China
GSK Investigational Site
RECRUITING

Yangzhou, 225001, China
GSK Investigational Site
RECRUITING

Yinchuan, China
GSK Investigational Site
RECRUITING

Zhanjiang, 524045, China
GSK Investigational Site
RECRUITING

Zhengzhou, 450052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.